<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2463">
  <stage>Registered</stage>
  <submitdate>17/08/2009</submitdate>
  <approvaldate>17/08/2009</approvaldate>
  <nctid>NCT00961766</nctid>
  <trial_identification>
    <studytitle>Evaluate the Safety, Tolerability and Pharmacokinetics of BG00010 (Neublastin) Administered to Sciatica Participants</studytitle>
    <scientifictitle>Phase 1: A Single-Center, Randomized, Blinded, Placebo-Controlled, Single-Administration, Sequential-Cohort, Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BG00010 (Neublastin) Administered to Sciatica Participants</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>103NS101</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Sciatica</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - BG00010 (Neublastin)
Treatment: drugs - Placebo

Experimental: BG00010 (Neublastin) - Participants may be randomized to escalating doses of BG00010 or matching placebo

Placebo Comparator: Placebo - Participants may be randomized to escalating doses of BG00010 or matching placebo


Treatment: drugs: BG00010 (Neublastin)
Single dose, weight-based IV administration

Treatment: drugs: Placebo
Single dose IV matched placebo

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number of participants experiencing Adverse Events (AEs)</outcome>
      <timepoint>Up to 56 days post dosing</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change in Likert numerical pain rating scale</outcome>
      <timepoint>Up to 56 days post dosing</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change in Quantitative Sensory Test (QST) - QST; Vibratory, Cool Thermal,</outcome>
      <timepoint>Up to 28 days post dosing</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change in Intra Epidermal Nerve Fiber Density (IENFD)</outcome>
      <timepoint>Up to 28 days post dosing</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Maximum observed serum concentration (Cmax)</outcome>
      <timepoint>Up to 5 days post dosing</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Area under the serum concentration curve (AUC)</outcome>
      <timepoint>Up to 5 days post dosing</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Terminal half-life (t1/2)</outcome>
      <timepoint>Up to 5 days post dosing</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Total body clearance (CL)</outcome>
      <timepoint>Up to 5 days post dosing</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Steady state volume of distribution (Vss)</outcome>
      <timepoint>Up to 5 days post dosing</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Key 

          -  Must have a diagnosis of unilateral sciatica, determined by the Investigator. Sciatica
             symptoms must be present for 6 or more weeks prior to the Screening Visit.

          -  Must have a body mass index (BMI) between 18 kg/m2 and 32 kg/m2.

          -  Must rate their pain at &gt;40 mm on the 100 mm Visual Analog Scale (VAS) of the
             Short-Form McGill Pain Questionnaire (SF-MPQ)at the Screening and Baseline Visits.

        Key</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  History of malignancy or clinically significant (as determined by the Investigator)
             allergies, cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic,
             urologic, pulmonary, neurologic (not related to sciatica), dermatologic,
             rheumatic/joint, psychiatric, renal, and/or other major disease.

          -  History of signs or symptoms of peripheral neuropathy, other than symptoms of
             sciatica.

          -  History of severe allergic or anaphylactic drug-related reactions. NOTE: Other
             protocol defined Inclusion/Exclusion criteria may apply</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>48</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/02/2012</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <hospital>Research Site - Adelaide</hospital>
    <postcode>5000 - Adelaide</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Biogen</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary objective of the study is to determine the safety/tolerability profile, systemic
      PK behavior, and immunogenicity of single IV and SC administrations of BG00010 to sciatica
      participants.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00961766</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Medical Director</name>
      <address>Biogen</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>